List of Excipients in Branded Drug NABUMETONE

Generic Drugs Containing NABUMETONE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	nabumetone	0115-1657	CELLULOSE, MICROCRYSTALLINE
Amneal Pharmaceuticals of New York LLC	nabumetone	0115-1657	HYPROMELLOSE 2910
Amneal Pharmaceuticals of New York LLC	nabumetone	0115-1657	POLYETHYLENE GLYCOL 400
Amneal Pharmaceuticals of New York LLC	nabumetone	0115-1657	POLYETHYLENE GLYCOL 6000
Amneal Pharmaceuticals of New York LLC	nabumetone	0115-1657	SILICON DIOXIDE
Amneal Pharmaceuticals of New York LLC	nabumetone	0115-1657	SODIUM LAURYL SULFATE
Amneal Pharmaceuticals of New York LLC	nabumetone	0115-1657	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in NABUMETONE?

# Of NDCs	Excipient
1	AMMONIUM LAURETH-5 SULFATE
97	CELLULOSE, MICROCRYSTALLINE
1	CI 77891
4	COLLOIDAL SILICON DIOXIDE
8	CROSCARMELLOSE SODIUM
5	D&C YELLOW NO. 10
1	FD&C YELLOW NO. 6

Nabumetone Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Nabumetone is a mature, genericized nonsteroidal anti-inflammatory drug (NSAID) with limited active-ingredient patent value and a larger opportunity in formulation execution. Commercial differentiation is most credible in tablet robustness, dissolution control, swallowability, packaging, supply reliability, and lifecycle extensions rather than in a new chemical entity or conventional generic launch.

The core formulation challenge is that nabumetone is a poorly water-soluble, neutral prodrug converted in vivo to the active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA). Excipients must support uniform tablet manufacture and reliable dissolution without creating unnecessary regulatory or supply-chain complexity. FDA-approved products are primarily immediate-release tablets in 500 mg and 750 mg strengths.[1][2]

What is nabumetone and why do excipients matter?

Nabumetone is an orally administered prodrug used for osteoarthritis and rheumatoid arthritis. It is converted hepatically to 6-MNA, the pharmacologically active metabolite associated with cyclooxygenase inhibition.[1]

Unlike acidic NSAIDs such as ibuprofen, naproxen, and diclofenac, nabumetone is a nonacidic compound. The absence of a carboxylic acid in the parent molecule affects solubility, gastrointestinal exposure, salt-selection options, and formulation design.

Key formulation implications include:

• A need to manage dissolution from a poorly soluble active ingredient.
• Sensitivity to particle-size distribution and blending uniformity.
• Potential use of wetting agents or disintegrant systems to improve tablet performance.
• A preference for robust direct-compression or dry-granulation platforms where flow and compaction permit.
• Limited commercial value in conventional tablet excipient substitution unless the change improves manufacturing, patient use, or regulatory positioning.

Nabumetone is generally formulated as an immediate-release tablet. A formulation that materially changes release characteristics would require a separate regulatory strategy and could create bioequivalence and clinical-performance risks.

What excipients are used in nabumetone tablets?

Public product labels identify excipients, but the exact quantitative composition is usually proprietary. FDA labeling for RELAFEN and generic nabumetone products identifies conventional tablet excipients that may include cellulose derivatives, starches, povidone, sodium starch glycolate, magnesium stearate, colloidal silicon dioxide, and coating materials, depending on the manufacturer.[1][2][3]

Excipient function	Typical candidates	Commercial purpose
Diluent or compression aid	Microcrystalline cellulose, lactose, dibasic calcium phosphate	Tablet mass, flow, hardness
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Granule and tablet strength
Disintegrant	Sodium starch glycolate, crospovidone, croscarmellose sodium	Rapid tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Wetting or dissolution aid	Polysorbate, sodium lauryl sulfate, selected surfactants	Improved wetting of nabumetone particles
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Appearance, protection, swallowability
Opacifier or colorant	Titanium dioxide, iron oxides	Product identification and light protection

The formulation team should treat label-listed excipients as a competitive map, not as a complete recipe. FDA’s Inactive Ingredient Database can support precedent analysis by route, dosage form, and ingredient, but it does not establish that a proposed concentration will be acceptable in every product.[4]

What is the best excipient strategy for a new nabumetone generic?

The lowest-risk strategy is an immediate-release tablet using established excipients with broad oral-solid-dose precedent. The target should be comparable dissolution and bioavailability with a manufacturing process that avoids unnecessary formulation novelty.

Option 1: Direct-compression formulation

Direct compression can reduce processing steps, water exposure, and manufacturing cost. A practical platform would combine:

• Microcrystalline cellulose or another compression aid.
• A high-performance disintegrant.
• Colloidal silicon dioxide for flow.
• Magnesium stearate at a controlled concentration and mixing time.
• A film coat for identification and swallowability.

The main risk is poor flow or segregation if the active ingredient has unfavorable particle morphology or density. Content-uniformity work should focus on active-to-excipient density differences, blend segregation, and tablet weight variation.

Option 2: Dry granulation

Roller compaction can improve flow, reduce segregation, and support high-throughput manufacturing without aqueous processing. It is attractive where nabumetone’s particle characteristics prevent consistent direct compression.

The principal risks are overcompaction, reduced tablet porosity, slower disintegration, and dissolution loss. Granule solid fraction and compression force should be controlled against dissolution rather than hardness alone.

Option 3: Wet granulation

Wet granulation can improve content uniformity and tablet strength but adds process complexity. It may be justified when direct compression and dry granulation fail to produce acceptable uniformity or dissolution.

The process should avoid excessive binder levels and overwetting. A dense granule can delay drug release from a poorly soluble active. Wet granulation also increases drying, solvent, microbial-control, and scale-up requirements.

Option 4: Solubility-enhancing formulation

A surfactant, micronized active, solid dispersion, or co-processed excipient system may improve dissolution. This approach has the greatest potential to create a differentiated product, but it also increases development and regulatory risk.

Potential technologies include:

• Micronization or controlled particle engineering.
• Surfactant-assisted wetting.
• Amorphous solid dispersion.
• Co-crystal or salt-like solid-state approaches, where chemically and legally appropriate.
• Lipid-based delivery systems for selected development programs.

For a standard generic, these approaches are usually commercially unattractive unless the reference-product dissolution profile is difficult to match or the sponsor is pursuing an improved product. A novel solid state may also trigger additional characterization, stability, bioequivalence, and intellectual-property analysis.

What formulation patents protect nabumetone products?

The major patent opportunity for nabumetone is formulation-specific rather than compound-specific. Potentially protectable subject matter includes:

• Particle-size-controlled nabumetone.
• Solid dispersions or co-amorphous systems.
• Modified-release tablets.
• Multiparticulate dosage forms.
• Taste-masked or orally disintegrating products.
• Combination products with gastroprotective agents.
• Manufacturing processes that produce a defined dissolution or solid-state profile.
• Packaging systems that improve stability or moisture protection.

A conventional 500 mg or 750 mg immediate-release tablet using standard excipients is unlikely to support broad, commercially powerful patent claims unless the formulation has a measurable, non-obvious performance advantage.

A stronger patent package would require claims tied to objective attributes, such as:

• A defined particle-size distribution.
• A specified polymorph or amorphous content.
• A dissolution profile over multiple time points.
• A quantified bioavailability improvement.
• A narrow but reproducible excipient ratio.
• Stability performance under defined conditions.

Patent value depends on enforceability and design-around difficulty. A claim limited to a common excipient, such as magnesium stearate or microcrystalline cellulose, generally has low strategic value. A claim covering a specific solid-state form or manufacturing sequence can be more defensible if competing products cannot easily replicate the result.

When does nabumetone lose exclusivity?

Nabumetone lost practical U.S. market exclusivity years ago. RELAFEN, the original branded product, was approved by FDA in 1991, and generic nabumetone tablets are widely marketed.[1][5]

Exclusivity category	Nabumetone status
Active pharmaceutical ingredient	Long genericized
Original U.S. approval	1991
Conventional immediate-release tablets	Open to generic competition
Orange Book patent barrier	No material barrier expected for standard generic entry
Pediatric exclusivity	Not commercially relevant to current generic strategy
Biosimilar pathway	Not applicable
Formulation-specific patents	Product- and jurisdiction-dependent

FDA’s Orange Book remains the controlling source for listed patents and regulatory exclusivity. A sponsor should review the current listing for RELAFEN and each relevant reference-listed product before filing or launching.[5]

What is the Orange Book status of nabumetone?

Nabumetone is regulated as a small-molecule oral solid, not a biologic. The principal regulatory pathway is an abbreviated new drug application (ANDA) referencing the applicable reference-listed drug.

The commercial consequences are straightforward:

• An ANDA applicant must establish pharmaceutical equivalence and bioequivalence.
• Paragraph IV certification is only relevant if a listed patent remains active and applicable.
• A Paragraph IV challenge could create litigation exposure, but the mature status of nabumetone reduces the likelihood of a meaningful current patent dispute for a conventional tablet.
• A formulation that differs materially from the reference product may require a 505(b)(2) pathway rather than a routine ANDA.

For a conventional generic, the critical regulatory work is likely to involve dissolution, bioequivalence, manufacturing controls, stability, and inactive-ingredient justification rather than patent litigation.

What generic entry risks exist for nabumetone?

The largest risks are technical and commercial.

Dissolution and bioequivalence risk

Poor solubility can make dissolution sensitive to particle size, granulation, lubricant level, tablet porosity, and disintegrant selection. Small changes in magnesium stearate mixing or compression force can affect wetting and release.

A development program should establish a design space linking:

• Active particle size.
• Blend uniformity.
• Granule density.
• Tablet tensile strength.
• Disintegration time.
• Dissolution across relevant pH conditions.
• Stability after humidity exposure.

Manufacturing risk

Nabumetone tablets are likely to compete in a low-price market. Any formulation that requires specialized equipment, narrow process controls, or expensive excipients can lose margin rapidly.

The best commercial formulation usually has:

• Multiple qualified suppliers.
• Low excipient cost.
• High tablet yield.
• Limited coating complexity.
• Stable dissolution after long-term storage.
• Compatibility with existing high-speed tablet presses.

Supply-chain risk

Excipient selection should account for supplier concentration, pharmacopeial grade availability, regional sourcing, and change-control burden. A formulation that relies on a single specialty surfactant or co-processed material can create avoidable continuity risk.

What commercial opportunities exist beyond a standard generic?

Nabumetone’s low active-ingredient cost creates opportunities only where formulation or channel economics support a premium.

Patient-friendly tablets

A lower-weight, thinner, easier-to-swallow tablet could improve adherence and support institutional or retail differentiation. Film-coating optimization may provide value without changing the release profile.

Orally disintegrating tablets

An orally disintegrating nabumetone product could target patients with swallowing difficulty. The development challenge is dose loading: 500 mg or 750 mg of active ingredient creates a large tablet or rapidly dispersible unit. Taste, mouthfeel, friability, and dose uniformity would be central risks.

Modified-release products

A once-daily or controlled-release product could offer a differentiated dosing profile. It would require new clinical or bioequivalence work and could face a 505(b)(2) pathway. The opportunity is larger than for a standard generic, but the development cost and regulatory uncertainty are also higher.

Combination products

Potential combinations with gastroprotective agents or other chronic-therapy products could address adherence and prescribing convenience. Such products would require careful interaction, dosing, labeling, and clinical justification. They could also face a crowded competitive field involving established NSAID and proton-pump-inhibitor combinations.

Contract manufacturing and private label

The strongest near-term opportunity may be cost-efficient supply for distributors, health systems, and private-label buyers. A robust formulation with reliable supply and multiple package configurations can compete even when the molecule itself has little differentiation.

How does nabumetone compare with competing NSAIDs?

Attribute	Nabumetone	Ibuprofen	Naproxen	Diclofenac
Chemical type	Nonacidic prodrug	Propionic-acid NSAID	Propionic-acid NSAID	Acetic-acid NSAID
Common oral forms	Immediate-release tablets	Tablets, capsules, suspensions	Tablets, capsules, suspensions	Tablets, capsules, topical forms
Formulation challenge	Poor-solubility dissolution and tablet robustness	Broad dosage-form competition	Broad generic competition	Multiple release and delivery systems
Generic competition	High	Very high	Very high	Very high
Differentiation potential	Modified release, patient-friendly formats	Pediatric and OTC formats	Dosing and combination products	Topical and extended-release products
Biosimilar relevance	None	None	None	None

Nabumetone has less consumer-brand momentum than ibuprofen and fewer dosage-form opportunities than diclofenac. Its advantage for a manufacturer is development simplicity in a conventional tablet, not a large premium market.

What patent litigation and Paragraph IV risks affect nabumetone?

Current commercial risk is more likely to arise from pricing, supply contracts, manufacturing quality, or product liability than from a live compound patent dispute. Conventional nabumetone tablets have been genericized for decades.

A Paragraph IV strategy would make sense only if a relevant, unexpired patent covered a specific reference product or formulation. For a standard immediate-release ANDA, the applicant should expect legal review of:

• Orange Book-listed patents.
• Any formulation or method-of-use patents linked to the reference product.
• Non-Orange-Book patents that could support litigation.
• Patent term adjustments or extensions.
• Settlement restrictions affecting launch timing.

Because nabumetone is a small molecule, biosimilar litigation does not apply. Any patent risk is conventional Hatch-Waxman or non-regulatory patent litigation, not the Biologics Price Competition and Innovation Act framework.

How strong is the nabumetone patent estate?

The estate is weak for the active ingredient and potentially moderate for narrowly defined new formulations.

Asset type	Strategic strength
Original nabumetone compound patent	Expired or commercially obsolete
Standard immediate-release tablet	Low
Novel dissolution-enhancing system	Moderate if performance is demonstrated
Modified-release product	Moderate to strong if clinically differentiated
Orally disintegrating tablet	Moderate, but vulnerable to design-around
Combination product	Product-specific
Manufacturing process	Moderate if process-specific and difficult to replicate
Packaging and stability system	Usually narrow

The strongest value lies in a formulation that produces measurable clinical or manufacturing benefits and cannot be reproduced by changing one conventional excipient.

What is the recommended commercial strategy?

A two-track strategy is appropriate:

1. Develop a low-cost immediate-release generic using established excipients, with direct compression or dry granulation selected through process data.
2. Screen one differentiated platform, such as a smaller swallowable tablet, orally disintegrating dosage form, or controlled-release product, only if market research supports a premium or channel advantage.

The base generic should prioritize dissolution robustness, supplier redundancy, and low conversion cost. The differentiated program should proceed only with early proof of improved exposure, adherence, dosing convenience, or manufacturing economics.

Key Takeaways

• Nabumetone is a mature small-molecule NSAID with no biosimilar pathway.
• The commercial opportunity is formulation-led, not molecule-led.
• Poor solubility makes particle size, wetting, disintegration, compression, and lubrication important development variables.
• Direct compression or dry granulation is likely to offer the best cost-risk balance for a conventional generic.
• Novel excipient systems can improve dissolution but may increase ANDA, 505(b)(2), and IP complexity.
• Standard immediate-release tablets have limited patent strength and limited pricing power.
• Modified-release, orally disintegrating, patient-friendly, and private-label products offer the clearest adjacent opportunities.
• Current FDA Orange Book review is required before filing any Paragraph IV certification.
• Manufacturing reliability and low cost are likely to matter more than compound patent protection.

FAQs

Can nabumetone be formulated as an oral suspension?

Yes, but the product would require control of sedimentation, redispersibility, taste, dose uniformity, preservative strategy, and chemical and physical stability. The high active dose may make a suspension less convenient than tablets.

Is micronized nabumetone commercially attractive?

Micronization can improve dissolution by increasing surface area, but it may worsen powder flow, electrostatic behavior, segregation, and handling risk. It is attractive only if dissolution or bioequivalence data show a meaningful benefit.

Can nabumetone use a salt formulation?

Nabumetone is a neutral prodrug, so conventional salt formation may provide less obvious value than it would for an ionizable acidic or basic drug. Solid-state engineering, co-crystals, or particle modification may be more relevant.

Does a new nabumetone excipient combination require a new patent?

No. A new excipient combination is not automatically patentable. Patentability depends on novelty, non-obviousness, enablement, and a defensible relationship between the formulation and its demonstrated performance.

What is the most attractive nabumetone product for a contract manufacturer?

A cost-optimized 500 mg and 750 mg immediate-release tablet with reliable dissolution, multiple excipient suppliers, efficient coating, and flexible bottle or blister packaging is the lowest-risk commercial product. A differentiated dosage form offers higher upside but requires a separate regulatory and market-access case.

References

1. U.S. Food and Drug Administration. (1991). Relafen (nabumetone) prescribing information. FDA.

2. DailyMed. (n.d.). Nabumetone tablet labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

5. U.S. Food and Drug Administration. (n.d.). Electronic Orange Book database. FDA.